CU20210077A7 - Extractos bacterianos estables como fármacos - Google Patents

Extractos bacterianos estables como fármacos

Info

Publication number
CU20210077A7
CU20210077A7 CU2021000077A CU20210077A CU20210077A7 CU 20210077 A7 CU20210077 A7 CU 20210077A7 CU 2021000077 A CU2021000077 A CU 2021000077A CU 20210077 A CU20210077 A CU 20210077A CU 20210077 A7 CU20210077 A7 CU 20210077A7
Authority
CU
Cuba
Prior art keywords
drugs
bacterial extracts
stable bacterial
stable
extracts
Prior art date
Application number
CU2021000077A
Other languages
English (en)
Inventor
Jacques Bauer
Christian Pasquali
Original Assignee
Om Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Pharma Sa filed Critical Om Pharma Sa
Publication of CU20210077A7 publication Critical patent/CU20210077A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/08—Reducing the nucleic acid content
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<p>La presente invención se refiere a preparaciones de extractos bacterianos estables, métodos de preparación de los mismos y formulaciones farmacéuticas que los comprenden.</p>
CU2021000077A 2019-03-14 2020-03-12 Extractos bacterianos estables como fármacos CU20210077A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19162912 2019-03-14
PCT/EP2020/056742 WO2020182970A1 (en) 2019-03-14 2020-03-12 Process for making stable bacterial extracts and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
CU20210077A7 true CU20210077A7 (es) 2022-04-07

Family

ID=65991511

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000077A CU20210077A7 (es) 2019-03-14 2020-03-12 Extractos bacterianos estables como fármacos

Country Status (19)

Country Link
US (2) US11801271B2 (es)
EP (2) EP4234026A3 (es)
JP (1) JP2022525177A (es)
KR (1) KR20210141546A (es)
CN (1) CN113840615A (es)
AU (1) AU2020235261A1 (es)
BR (1) BR112021018006A2 (es)
CA (1) CA3132564A1 (es)
CL (1) CL2021002401A1 (es)
CO (1) CO2021013677A2 (es)
CR (1) CR20210515A (es)
CU (1) CU20210077A7 (es)
IL (1) IL286215A (es)
MA (1) MA55291A (es)
MX (1) MX2021010912A (es)
PE (1) PE20212261A1 (es)
SG (1) SG11202109937UA (es)
WO (1) WO2020182970A1 (es)
ZA (1) ZA202106914B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613665A (zh) * 2019-03-14 2021-11-05 Om药物公司 治疗和/或预防哮喘、哮喘恶化、过敏性哮喘和/或与呼吸***病症相关的微生物群相关的病症的方法
TW202304485A (zh) * 2021-04-12 2023-02-01 香港中文大學 用於增強免疫力的方法和組合物
WO2022233441A1 (en) * 2021-05-07 2022-11-10 Symrise Ag Novel bacterial ferment of lactobacillus species
EP4134426A1 (en) * 2021-08-13 2023-02-15 Symrise AG Novel bacterial ferment of lactobacillus species
WO2023120547A1 (ja) * 2021-12-22 2023-06-29 株式会社明治 二次性感染症の予防又は発症リスクを低減するための組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
BR8603576A (pt) 1985-07-30 1987-03-04 Glaxo Group Ltd Dispositivos para administrar medicamentos a pacientes
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
CH685498A5 (fr) 1992-02-14 1995-07-31 Om Lab Sa Extrait de macromolécules bactériennes, procédé pour sa préparation et composition pharmaceutique contenant cet extrait.
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US7171965B2 (en) 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
US6994083B2 (en) 2001-12-21 2006-02-07 Trudell Medical International Nebulizer apparatus and method
BRPI0518662B1 (pt) * 2004-11-30 2020-12-22 Merial, Inc. processo e aparelho para lise de compostos biológicos
WO2008085549A2 (en) * 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
SI2117587T1 (en) 2007-03-05 2018-04-30 Om Pharma Bacterial extract for disorders of the digestive or urinary tract and the process for its preparation
PL2114421T3 (pl) * 2007-03-05 2018-07-31 Om Pharma Ekstrakt bakteryjny do stosowania względem zaburzeń oddechowych i sposób jego wytwarzania
GB0818453D0 (en) * 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
ES2356883B1 (es) 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
CA2733249A1 (en) * 2008-09-04 2010-03-11 Om Pharma Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
RU2425691C1 (ru) 2010-07-15 2011-08-10 ВАКЕ спол с.р.о. Аэрозольный препарат на основе апротинина для лечения вирусных респираторных инфекций
CN101979541A (zh) * 2010-10-28 2011-02-23 徐堤 一种快速共价闭合环状dna纯化试剂盒
MX2019006848A (es) * 2016-12-13 2019-10-07 Defensin Therapeutics Aps Metodos para tratar condiciones inflamatorias de los pulmones.

Also Published As

Publication number Publication date
US11801271B2 (en) 2023-10-31
JP2022525177A (ja) 2022-05-11
CR20210515A (es) 2022-03-28
CL2021002401A1 (es) 2022-04-08
US20230346855A1 (en) 2023-11-02
WO2020182970A1 (en) 2020-09-17
ZA202106914B (en) 2023-10-25
BR112021018006A2 (pt) 2021-11-16
CA3132564A1 (en) 2020-09-17
SG11202109937UA (en) 2021-10-28
US20210401902A1 (en) 2021-12-30
CO2021013677A2 (es) 2021-10-20
AU2020235261A1 (en) 2021-09-16
IL286215A (en) 2021-10-31
MX2021010912A (es) 2021-10-01
KR20210141546A (ko) 2021-11-23
CN113840615A (zh) 2021-12-24
EP4234026A3 (en) 2024-07-03
EP4234026A2 (en) 2023-08-30
EP3937957A1 (en) 2022-01-19
MA55291A (fr) 2022-01-19
PE20212261A1 (es) 2021-11-29

Similar Documents

Publication Publication Date Title
CU20210077A7 (es) Extractos bacterianos estables como fármacos
ECSP19029982A (es) Moduladores de calpaínas y usos terapeuticos de los mismos
CO2018003477A2 (es) Anticuerpos anti-pd1 y métodos de uso
EA201890817A1 (ru) Кристаллические формы бета-никотинамида мононуклеотида
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
MX2019000427A (es) Formas de dosificacion oral de cannabinoide de alta concentracion.
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
DOP2015000051A (es) Formulaciones acuosas estables de adalimumab
CL2018003527A1 (es) Conjugados de anticuerpo anti-egfr y fármaco.
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CY1117881T1 (el) Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
AR115359A1 (es) Preparaciones microbianas para plantas, composiciones y formulaciones que las comprenden y sus usos
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
GEP20237486B (en) Formulations of copanlisib
GT201600252A (es) Derivados de naftiridinadiona
NI202000028A (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112018071363A2 (pt) composições farmacêuticas orais de nicotinamida
CL2018002368A1 (es) Formulaciones de oritavancina